Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 

Final Agenda 


Strategies for Clinical Oncology 

Day 1 | Day 2 | Day 3 | Download Brochure 

Recommended Pre-Conference Short Courses * 

(SC5) Early Drug Development and First-in-Human Dose Regimen  

*Separate Registration Required. 



Wednesday, February 23 

7:00 am Registration and Morning Coffee

8:00 Plenary Keynotes - Details 

9:40 Grand Opening Refreshment Break in the Exhibit Hall




11:00 Chairperson’s Opening Remarks: James Gulley, NCI/NIH

11:10 Sipuleucel-T Immunotherapy for Advanced Prostate Cancer

David L. Urdal, Ph.D., Chief Scientific Officer, Dendreon Corporation 

Will describe the clinical efficacy and safety data supporting FDA approval of the first autologous cellular immunotherapy approved for the treatment of cancer. Data on immune response, product potency, and correlation of potency measures with clinical outcomes will be described.

11:40 Cancer Vaccines: New Paradigm in Changing Cancer to a Chronic Disease

Helen Sabzevari, Ph.D., Global Head, Oncology-Immunotherapy, EMD-Serono, Inc. 

12:10 pm Ipilimumab Development: Contribution to a New Immunotheray Paradigm

Axel HoosAxel Hoos, M.D., Ph.D., Medical Lead, Immunology/Oncology, Bristol-Myers Squibb

Ipilimumab development has contributed valuable lessons to the evolution of a new development paradigm for cancer immunotherapies as spearheaded by the Cancer Immunotherapy Consortium. This new paradigm encompasses new tools and development principles for immuno-oncology. It offers a better defined path for development of new therapies in this space.



12:40 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

1:45 Dessert in the Exhibit Hall

2:20 HN1: a Novel Human Monoclonal Antibody Targeting Mesothelin for Cancer Therapy

Mitchell HoMitchell Ho, Ph.D., Head, Antibody Therapy Unit, LMB, National Cancer Institute, National Institutes of Health

We recently generated HN1, a fully human IgG, that binds mesothelin with high affinity. The HN1 epitope is different from that of SS1, a mouse Fv used to develop an immunotoxin (SS1P) and a chimeric antibody (MORAb-009) that are currently in clinical trials. HN1 binds strongly to cell surface-associated mesothelin on mesothelioma, ovarian cancer, lung adenocarcinoma and pancreatic cancer cells. HN1 kills cancer cells with very strong antibody-dependent cell-mediated cytotoxicity and has potential for mesothelin-expressing cancer treatment.


2:50 Initial Experience With Autologous Heat Shock Protein Vaccine for Brain Tumor Patients

Andrew T. Parsa, M.D., Ph.D., Associate Professor in Residence of Neurological Surgery, Reza & Georgianna Khatib Endowed Chair in Skull Based Tumor Surgery; Principal Investigator, Brain Tumor Research Center, University of California, San Francisco

3:20 Genomics-Guided Personalized Immunotherapy of Human Cancers: Rationale & Challenges

Pramod Srivastava, Ph.D., Director, Center for Cancer & Infectious Disease, University of Connecticut

High throughput DNA sequencing, and sophisticated informatics tools provide new opportunities for immunotherapy of human cancer. The scientific and clinical rationale for these opportunities, as well as the novel logistical and regulatory challenges expected of them, shall be discussed.

3:50 Sponsored Presentations (Opportunities Available)  

4:20 Reception in the Exhibit Hall (Sponsorship Available)

5:20 Breakout Discussions in the Exhibit Hall

Concurrent Problem Solving Break-Out Sessions are interactive, problem solving discussions hosted by a moderator to discuss a topic in depth.  The discussions are open to all attendees, sponsors, exhibitors, and speakers and provide a forum for discussing key issues and meeting potential partners. Please pick a topic of your choice and join in.  

Imaging as a Co-Developed Diagnostic to Meet FDA Standards

Rikki N. Waterhouse, Ph.D., Senior Group Leader, Abbott

Picking Perfect Patients

James L. Gulley, M.D., Ph.D., F.A.C.P., Director, Clinical Trials Group, Tumor Immunology and Biology, NCI/NIH

CTC Methods Development Strategies for New Biomarkers

Lihua Wang, Senior Scientist, Pharmacodynamic Assay Development Section, Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Directorate, SAIC-Frederick, Inc., NCI-Frederick


6:20 Close of Day

Day 1 | Day 2 | Day 3 | Download Brochure